Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 90 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Synthroid Clear all
Recruiting Not applicable Interventional

A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients

NCT03977207
View directory record Official record
Conditions
Thyroid; Functional Disturbance, Hypothyroidism, Hemodialysis
Interventions
Levothyroxine Sodium, Placebos
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 5, 2026, 4:06 PM EDT
Completed Phase 3 Interventional

Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.

NCT00158990
View directory record Official record
Conditions
Major Depression, Bipolar Disorder, Unipolar Depression
Interventions
triiodothyronine, sertraline
Drug
Lead sponsor
Hadassah Medical Organization
Other
Eligibility
18 Years to 70 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2007 · Synced Sep 5, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NCT01391962
View directory record Official record
Conditions
Sarcoma, Alveolar Soft Part
Interventions
Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 5, 2026, 4:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers

NCT00336102
View directory record Official record
Conditions
Breast Cancer, Fatigue, Hypothyroidism
Interventions
physiologic testing, fatigue assessment and management, management of therapy complications
Other · Procedure
Lead sponsor
University of South Florida
Other
Eligibility
20 Years to 80 Years · Female only
Enrollment
541 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
41
States / cities
Phoenix, Arizona • Greeley, Colorado • Loveland, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Sep 5, 2026, 4:06 PM EDT
Recruiting Phase 2 Interventional

Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

NCT05526144
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Liver Fibrosis
Interventions
Synthroid, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 5, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Liothyronine (T3) for Bipolar Depression

NCT00790738
View directory record Official record
Conditions
Depression, Bipolar Disorder
Interventions
Liothyronine (T3), placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 5, 2026, 4:06 PM EDT
Completed Not applicable Interventional Results available

Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism

NCT02374593
View directory record Official record
Conditions
Congenital Hypothyroidism
Interventions
Levothyroxine, Ultrasound
Drug · Device
Lead sponsor
Erica Eugster
Other
Eligibility
Up to 2 Weeks
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 8, 2017 · Synced Sep 5, 2026, 4:06 PM EDT
Completed Phase 1 Interventional

Effects of Triiodothyronine (T3) in Ischemic Heart Failure

NCT05384847
View directory record Official record
Conditions
Heart Failure
Interventions
Thyroid hormone T3, Control Group
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 5, 2026, 4:06 PM EDT
Terminated Phase 4 Interventional Results available

Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy

NCT02946918
View directory record Official record
Conditions
Thyroid Cancer, Postsurgical Hypothyroidism
Interventions
Levothyroxine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Sep 5, 2026, 4:06 PM EDT
Active, not recruiting Phase 2 Interventional

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
View directory record Official record
Conditions
Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions
Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 5, 2026, 4:06 PM EDT
Withdrawn Phase 4 Interventional

Levothyroxine in Pregnant SLE Patients

NCT01276782
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Levothyroxine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2015 · Synced Sep 5, 2026, 4:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers

NCT03856970
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Microgestin®, Levothyroxine, Glyburide, Digoxin, IW-3718
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Sep 5, 2026, 4:06 PM EDT
Recruiting Phase 4 Interventional

Dosing of LT4 in Older Individuals

NCT06073665
View directory record Official record
Conditions
Hypothyroidism
Interventions
Levothyroxine Sodium
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 5, 2026, 4:06 PM EDT
Terminated No phase listed Observational Results available

Study of Possible Brain Hormone Problems After Open Heart Surgery in Infants

NCT00850720
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Blood draws
Other
Lead sponsor
Emory University
Other
Eligibility
Up to 1 Year
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Sep 5, 2026, 4:06 PM EDT
Completed Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism

NCT05412979
View directory record Official record
Conditions
Hypothyroidism
Interventions
ST-1891, Levothyroxine
Drug
Lead sponsor
Sention Therapeutics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
39
States / cities
Greenbrae, California • Newhall, California • Denver, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced Sep 5, 2026, 4:06 PM EDT
Completed Phase 2Phase 3 Interventional

Supraphysiological Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression

NCT01528839
View directory record Official record
Conditions
Bipolar Disorder
Interventions
L-Thyroxine, Placebo
Drug
Lead sponsor
Charite University, Berlin, Germany
Other
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Sep 5, 2026, 4:06 PM EDT
Completed No phase listed Observational

Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)

NCT01299337
View directory record Official record
Conditions
Depression
Interventions
T3
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 64 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Sep 5, 2026, 4:06 PM EDT
Active, not recruiting Phase 2 Interventional

Treatment of ARDS With Instilled T3

NCT04115514
View directory record Official record
Conditions
ARDS, Human, Lung, Wet, Thyroid, Pulmonary Edema, Lung Inflammation
Interventions
Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation., Non-intervention
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Edina, Minnesota • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 5, 2026, 4:06 PM EDT
Terminated No phase listed Observational

Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?

NCT02567877
View directory record Official record
Conditions
Postsurgical Hypothyroidism, Hypothyroidism
Interventions
thyroidectomy, levothyroxine in thyroidectomy patients
Procedure · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Sep 5, 2026, 4:06 PM EDT
Completed Phase 1 Interventional Results available

Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study

NCT02760056
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Liothyronine sodium, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 18, 2018 · Synced Sep 5, 2026, 4:06 PM EDT
Recruiting Phase 1 Interventional

Levothyroxine Supplementation for Heart Transplant Recipients

NCT06428097
View directory record Official record
Conditions
Heart Transplant Failure, Heart Transplant Infection
Interventions
Levothyroxine, Normal saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 5, 2026, 4:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Levothyroxine Sodium Tablets 300 μg to Synthroid® Tablets 300 μg

NCT00647855
View directory record Official record
Conditions
Healthy
Interventions
Levothyroxine Sodium Tablets 300 μg, Synthroid® Tablets 300 μg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 5, 2026, 4:06 PM EDT
Withdrawn Phase 4 Interventional

Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding

NCT02577367
View directory record Official record
Conditions
Hypothyroidism
Interventions
Levothyroxine
Drug
Lead sponsor
Jocelyne Karam
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 5, 2026, 4:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Developing Oral LT3 Therapy for Heart Failure - HFpEF

NCT04111536
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome
Interventions
liothyronine, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 5, 2026, 4:06 PM EDT